BNP Paribas Financial Markets’s Contineum Therapeutics CTNM Stock Holding History

BNP Paribas Financial Markets’s Portfolio CTNM Stock Details CTNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.29M	Buy	78,920 +39,041	+98%	+$512K	﹤0.01%	3140
2026 Q1	$521K	Sell	39,879 -24,349	-38%	-$327K	﹤0.01%	3569
2025 Q4	$734K	Buy	64,228 +64,008	+29,095%	+$730K	﹤0.01%	3323
2025 Q3	$2.58K	Sell	220 -78	-26%	-$629	﹤0.01%	5150
2025 Q2	$1.18K	Sell	298 -330	-53%	-$1.43K	﹤0.01%	5126
2025 Q1	$4.38K	Sell	628 -689	-52%	-$6.27K	﹤0.01%	4874
2024 Q4	$19.3K	Sell	1,317 -5,426	-80%	-$85.9K	﹤0.01%	4732
2024 Q3	$129K	Buy	6,743 +6,243	+1,249%	+$120K	﹤0.01%	3396
2024 Q2	$8.8K	Buy	+500	New	+$8.05K	﹤0.01%	3732

Other funds holding CTNM

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

BNP Paribas Financial Markets's CTNM Position: Q2 2026 in Review

BNP Paribas Financial Markets increased its Contineum Therapeutics (CTNM) stake by 98% in Q2 2026, buying an estimated $512K and bringing the position to 78,920 shares worth $1.29M. The position accounts for ﹤0.01% of the portfolio, ranked #3140.

BNP Paribas Financial Markets first reported a position in CTNM in Q2 2024 and has held it in 9 quarters since. 102 funds tracked by Wall St. Rank hold CTNM as of Q2 2026.

BNP Paribas Financial Markets held 78,920 shares of Contineum Therapeutics worth $1.29M as of Q2 2026.
BNP Paribas Financial Markets bought 39,041 Contineum Therapeutics shares in Q2 2026, an estimated $512K.
Contineum Therapeutics made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #3140 holding.
BNP Paribas Financial Markets first reported a position in Contineum Therapeutics in Q2 2024 and has held it in 9 quarters since.
102 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.